Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone

JUN WAN¹, WEI WU² and RENQUAN ZHANG¹

Departments of ¹Thoracic Surgery and ²Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China

Received September 17, 2015; Accepted December 7, 2015

DOI: 10.3892/or.2015.4541

Abstract. Local recurrence of lung cancer following radiofrequency ablation (RFA) treatment is common. The aims of the present study were to assess how RFA treatment affects the growth of small cell lung cancer (SCLC) micrometastases in the transition zone (TZ) surrounding the ablated region and in the reference zones (RZs) of the ablated or unablated lobes and to identify the molecular mechanism(s) of lung cancer recurrence following RFA treatment. After lung micrometastases of human SCLCs had formed, RFA treatment was applied to the right upper lobe (RUL) of the lung in nude mice. Hypoxia inducible factor (HIF)-1α expression, proliferation and angiogenesis potential both in the TZ and RZ were evaluated over time. Separately, at day 1, 7 and 14 following RFA treatment, the growth of micrometastases showed an ~2-fold increase in the TZ compared to the RZ of the unablated lobe, as the right lower lobe (RLL) and the growth of micrometastases in the RZ of the RUL was also induced by RFA. In addition, accelerated tumor growth in the TZ was induced by HIF-1α, but was not associated with tissue angiogenesis potential. We concluded that local recurrences of SCLCs caused by overproliferation of micrometastases following RFA treatment were driven by HIF-1α, although angiogenesis was not the driving force in the TZ.

Introduction

For the treatment of lung cancer, surgical resection, consisting of a lobectomy and complete lymph node dissection, has long been considered the standard treatment for resectable tumors (1). However, it is estimated that only one-third of patients with non-small cell lung cancers (NSCLCs) are suitable candidates for curative resection (2). However, for small cell lung cancers (SCLCs), a histological subtype of lung cancers with unique biological and oncological features that differ significantly from NSCLCs, standard treatment usually consists of systemic chemotherapy and radiotherapy. Surgery in association with chemotherapy and radiotherapy is only indicated for a small subset of SCLCs presenting with limited disease progression (3). Although SCLCs are sensitive to radiotherapy and chemotherapy, patients remain in remission for a relatively short duration and the emergence of rapidly growing drug-resistant metastases are frequent in such patients. Therefore, treatments for SCLCs are more likely to incorporate multidisciplinary synthetic therapies (4).

Previous studies have indicated that human NCI-H446 SCLC cells are more sensitive to thermal treatment compared to NSCLC cells, and thermal treatment can augment the cytotoxicity of chemotherapeutic drugs (5). Radiofrequency ablation (RFA) is an example of a thermotherapy technique that is advanced, minimally invasive, and is used to treat several types of neoplasms. Its application to the treatment of lung tumors has received great interest (6). Lung tumors may be ideal targets for RFA, since the surrounding air in the adjacent normal lung parenchyma can provide an insulating effect, subsequently concentrating the RF energy within the tumor tissue (7). However, according to a previous study, RFA is associated with increased rates of local recurrence for lung tumors with large volumes, since it is difficult to reach sufficiently high temperatures in larger tumors and achieve complete tumor destruction, as the heat source is farther removed from the deeper sections of the tumor (8). Moreover, a rich tumor blood supply is another factor that influences local recurrence, as an abundant blood supply may help to dissipate the thermal energy and weaken the effects of ablation (8). However, as ablative devices are improved, satisfactory ablative margins will likely be achieved. Various scholars suggest...
that even when the tumor is completely destroyed/removed by RFA, residual viable tumor cells within the periphery of the ablated area may repopulate the tumor during a recurrence (9). Therefore, a new view was proposed that local recurrence of the tumor is a product of the biological behaviors of residual tumor cells, since proliferation and angiogenesis potential change with RFA. Overproliferation is mainly observed around areas of tissue necrosis and is associated with a hypoxic tissue microenvironment (10). Therefore, altering the biological characteristics of the hypoxic tissue microenvironment that develops following RFA may influence the local recurrence rate. Therefore, our goal was to observe the tissue microenvironment following RFA and its relationship to recurrence.

The most common patterns of recurrence were classified as local, intrapulmonary or distant. Local recurrence was defined as a recurrence within or at the margin of the ablation site. An intrapulmonary recurrence was defined as the presence of a new tumor within the same lobe as the initially ablated tumor that is separated from the original ablation zone. Distant recurrence was defined as newly identified lung cancer metastases within the other unablated lobe of the ipsilateral lung (11). According to these three patterns, we divided the right lobe that underwent RFA treatment into three distinct regions. We examined the transition zone (TZ) located at the margin of the ablation zone; tumors appearing here were considered a local recurrence. We also examined the reference zone (RZ) of the ablated lobe, which consisted of the unablated part in the lobe that underwent RFA treatment; tumors appearing here were considered an intrapulmonary recurrence. Finally, we examined the RZ on the ipsilateral side of the unablated lobe, which consisted of the unablated part in the lobe that underwent RFA treatment; tumors appearing here were considered a recurrence within or at the margin of the ablation site. An intrapulmonary recurrence was defined as newly identified lung cancer metastases within the other unablated lobe of the ipsilateral lung (11).

All animals were acclimated for at least 7 days prior to the intravenous (i.v.) injection of NCI-H446-Luc. On day 1, NCI-H446-Luc cells were collected and resuspended in phosphate-buffered saline (PBS; Thermo Fisher Scientific) at a concentration of 5x10^7 cells/ml. Tail vein injections of 100 µl of cell solution were administered to each mouse. Tumor metastasis was monitored by in vivo imaging at 1 or 3 weeks following the injection. Chloral hydrate (100 µl) was administered by intraperitoneal (i.p.) injection, and the procedure commenced after 5 min. After anesthesia, mice were imaged one at a time for 3 min each using an IVIS Lumina II in vivo imaging system (Caliper Life Sciences, a PerkinElmer Co., Hopkinton, MA, USA). Images were collected for further analysis.

RFA treatment and drug intervention. A multipole RF ablation instrument and bipolar ablation needle were purchased from Beijing Blade Opto-Electronic Technology Development Co., Ltd. In nude mice, a bipolar electrode (outer diameter 1.0 mm, active length 10 mm) was used for RFA at 2 W for 45 sec with complete puncture of the right lung upper lobe, which corresponded to a total energy output of 90 J. RF was applied for 5 min with the generator output titrated to maintain a designated tip temperature (70°C±2, 90 mA±20).

YC-1, 3-(5'-hydroxy-methyl-2'-furanyl)-1-benzylindazole (Sigma-Aldrich Co.), possesses antiplatelet activity and decreases hypoxia-induced HIF-1α accumulation and stability (15). Therefore, YC-1 was dissolved in saline and administered via i.p. injections at a preoperative dose of 100 mg/kg body weight, followed by postoperative doses of 30 mg/kg body weight.

PTK787/ZK-222584 (PTK/ZK; MedChem Express, Monmouth Junction, NJ, USA) is a non-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (16). PTK/ZK was dissolved in polyethylene glycol 400 and administered twice daily by i.p. injections at a dose of 50 mg/kg from 1 day prior to RFA.

Experimental design and tumor assay. The effect of RFA on the perinecrotic overproliferation of SCLC micrometastases in nude mouse lungs was assessed. This nude mouse model of human SCLC micrometastases was previously established (17). Altogether 150 mice (evenly divided into female and male genders) with established SCLC micrometastases were involved in the experiment and the experimental analysis, which was carried out in three stages at day 1, 7 and
14 following the RFA treatment. In each stage, 50 mice were randomized into five groups: the sham group; sham + YC-1 group; RFA group; RFA + YC-1 group; RFA + PTK/ZK group, and each group had 10 mice. The treatment plan was as follows. Tail vein injections of NCI-H446 cells in each animal occurred on day 0. RFA treatment began 3 weeks following the injection of tumor cells. Treatment with YC-1 or PTK/ZK was initiated one day before RFA treatment. Mice were individually sacrificed at day 1, 7 and 10 following RFA treatment (n=10/group/time point).

For tumor assays, we applied the methods of Nijkamp et al (16). Tumor load in the lung was scored as the pneumonic replacement area (PRA), which is the percentage of lung tissue that had been replaced by tumor tissue. The PRA in the TZ and RZ was measured. We defined the TZ based on preliminary histologic data, showing histologic characteristics in the TZ that were most abundant in the first 2 mm stretching from the edge of the central necrosis zone (CZ). RZ was defined as the remaining part of the ipsilateral lung tissue and included the RZ of the right lung upper lobe (RUL) and the RZ of the right lung lower lobe (RLL). All analyses were performed by at least two independent observers that were blinded to the treatment, and used an automated microscope with an interactive video overlay system (Leica Q-Prodit; Leica Microsystems, Rijswijk, The Netherlands). The scar tissue induced by RFA was excluded from analysis. For analysis of treatment with YC-1 and PTK/ZK, we compared the PRA ratios, the ratio between the PRA in the TZ and the PRA in the RZ. PRA ratios were used to reflect the level of tumor proliferation.

Immunohistochemistry detection for identification of human SCLC metastasis and HIF-1α, and CD34 expression in tumor tissues. All tumor tissues were sectioned into 4-µm slices, deparaffinized, and endogenous peroxidases were inhibited with 0.3% hydrogen peroxide in methanol for 30 min. Antigen retrieval was achieved by treating sections with 0.05% protease XIV for 5 min at 37°C. Sections were then incubated with a mouse anti-human NSE, HIF-1α and CD34 primary antibody (NSE, 1:50; HIF-1α, 1:1,000; CD34, 1:200 dilution; Wuhan Boster Biological Engineering Technology Co. Ltd.) overnight at 4°C. The slides were then incubated with a biotin-conjugated rabbit anti-mouse secondary antibody (1:1,000; Wuhan Boster Biological Engineering Technology Co. Ltd.) at room temperature for 45 min. The sections were subsequently incubated with a streptavidin-biotin-peroxidase complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA) at room temperature for 45 min. The reaction was visualized by applying chromogen diaminobenzidine (DAB) for 10 sec. Finally, the slides were counterstained with hematoxylin and mounted. The slides were examined with a Nikon Eclipse Ti microscope under a x40 objective (Nikon Instruments, Melville, NY, USA). Images of all
fields directly surrounding the lesion in one representative slide/tumor (6-13 fields/slide) were selected. The percentage of positive areas in each field was calculated with ImageJ software (National Institutes of Health, Bethesda, MD, USA).

**Figure 2.** Establishment of an experimental model of human SCLC metastasis and RFA treatment. (A and B) Following injection of NCI-H446-Luc cells, metastatic human SCLCs occurred in the bilateral lobe as shown by fluorescent display (the arrows show: a group, 1 week following injection; b group, no treatment; c group, 3 weeks following injection). (C and D) One week following the injection, histological slices of mouse lung showed that the tumor tissue cluster of human SCLCs occurred close to the pulmonary bronchium or vessel and NSE expression as positive area of DAB staining occurred within the metastasis. Then, 3 weeks following injection of human SCLC cells, metastasis widely grew within the lung tissue. (E and F) After anesthesia, the mice underwent right upper lobe puncture treatment. The depth of needle percutaneous puncture was 0.5 cm, and the necrotic ablation area formed was ~0.3-0.5 cm in diameter. (G) Histological slices of the tissue around the necrotic central area (CZ) showed that necrotic area transferred to the normal tissue and the transition zone (TZ) was formed. In this area the proliferation of the human SCLC metastasis was observed. (H) TZ was defined as the area stretching 2 mm outside the necrotic central zone. RZ was defined as the remaining part of the ipsilateral lung tissue and included the RZ of the right lung upper lobe (RUL) or the RZ of the right lung lower lobe (RLL).

**Figure 3.** Accelerated perilesional outgrowth of established micrometastases following RFA in the TZ and RZ. (A-C) Tumor growth at day 1, 7 and 14 following RFA treatment, expressed as the PRA in the TZ, defined as the area extending 2 mm outside the necrotic lesion in the RUL and RZ defined as the remaining part of the RUL and free area of the RLL. (A) Day 1: ***p=0.96, RZ of RFA group vs. RZ of sham group in RLL; *p=0.036, RZ of RFA group vs. RZ of sham group in RUL; **p=0.000, TZ vs. RZ in RUL and *p=0.008, TZ vs. RZ in RUL. (B) Day 7: ***p=0.87, RZ of RFA group vs. RZ of sham group in RLL; *p=0.021, RZ of RFA group vs. RZ of sham group in RUL; **p=0.001, TZ vs. RZ in RUL and *p=0.011, TZ vs. RZ in RUL. (C) Day 14: ***p=0.89, RZ of RFA group vs. RZ of sham group in RLL and *p=0.019, RZ of RFA group vs. RZ of sham group in RUL; **p=0.006, TZ vs. RZ in RUL and *p=0.026, TZ vs. RZ in RUL.

**Statistical analysis.** Statistical differences between groups were analyzed by a Student’s t-test and ANOVA for parametric data. Data are expressed as mean ± SEM. p<0.05 or p<0.01 was set as the level of statistical significance.
Results

RFA treatment effects and the TZ in lung tissue are morphologically distinct. We implanted a luciferase-labeled subline of the human variant SCLC cell line NCI-H446 orthotopically into the right lung of nude mice to establish an SCLC metastasis model. Three weeks following tail vein injection of SCLC cells, signs of systemic failure became increasingly more apparent, which included emaciation, lethargy and hunching of the back. Imaging was performed to assess fluorescence in the lung to locate and quantify the luciferase-labeled cancer cells, which could be used as an overall metric to quantify metastatic behavior (Fig. 2A and B). Histological observations revealed that the SCLC tumor tissue tended to cluster close to the pulmonary bronchium and vessel. In addition, human NSE expression was evaluated as the positive area of DAB staining observed within the tumor tissue. Since NSE is a specific marker of human SCLC cells, we used NSE expression to verify that the transplantation tumor was indeed derived from human SCLC cells (Fig. 2C). By 3 weeks following injection, human SCLC metastasis became prominent and pervasive throughout the lung tissue (Fig. 2D). All the mice were then anesthetized and subjected to RFA treatment in the RUL. The depth of needle percutaneous puncture was 0.5 cm and this formed the ablation area (Fig. 2E and F). Histological sections showed that the TZ stretched 2 mm outside the necrotic central area and any local recurrences often occurred in this area (Fig. 2G). With thermal ablation, the TZ and RZ in the RUL exhibited a different microenvironment as compared to RZ in the RLL, representing a different region of recurrence (Fig. 2H).

RFA accelerates the outgrowth of human SCLC micrometastases in the TZ and RZ of the lobe that underwent RFA. The first parameter analyzed was PRA, or the percentage of lung tissue that had been replaced by tumor tissue. Measuring the tumor size reflects proliferation. The PRA value of the RZ in the RLL showed that at day 1, 7 and 14 following RFA treatment, no significant changes could be observed when comparing the RFA group with the sham group (day 1 RFA, 14.8±2.98% vs. sham, 14.5±2.62%, p=0.96; day 7 RFA, 19.9±3.98% vs. sham, 19.2±3.52%, p=0.87; day 14 RFA, 27.9±4.39% vs. sham, 28.5±4.47%, p=0.89). These data indicated that RFA did not affect the outgrowth of metastases in the lobe not undergoing RFA treatment (Fig. 3A-C; Table IA-C). However, the RZ in the RUL showed a significantly higher PRA value in the RFA group when compared with the sham group (day 1 RFA, 19.6±3.46% vs. sham, 15.9±3.43%, p=0.036; day 7 RFA, 25.6±4.42% vs. sham, 18.9±3.99% p=0.021; day 14 RFA, 40.3±5.69% vs. sham, 29.8±4.53%, p=0.019) (Fig. 3A-C; Table IA-C).

| Table I. HPR value (%) in TZ and RZ at days 1, 7 and 14 following RFA. |
|---------------------------------------------------------------|
| **A, HPR value (%) in TZ and RZ at day 1 following RFA**      |
| Group | TZ     | RZ in RUL | RZ in RLL | P-value |
|-------|--------|-----------|-----------|---------|
| RFA   | 32.4±5.62 | 19.6±3.46 | 14.8±2.98 | p=0.000 TZ vs. RZ in RLL of RFA group |
|       |         |           |           | p=0.008 TZ vs. RZ in RUL of RFA group |
| Sham  | 15.9±3.43 | 14.5±2.62 |           | p=0.036 HPR of RZ in RUL RFA group vs. sham group |
|       |         |           |           | p=0.96 HPR of RZ in RLL RFA group vs. sham group |
| **B, HPR value (%) in TZ and RZ at day 7 following RFA**      |
| Group | TZ     | RZ in RUL | RZ in RLL | P-value |
|-------|--------|-----------|-----------|---------|
| RFA   | 39.8±7.62 | 25.6±4.42 | 19.9±3.98 | p=0.001 TZ vs. RZ in RLL of RFA group |
|       |         |           |           | p=0.011 TZ vs. RZ in RUL of RFA group |
| Sham  | 18.9±3.99 | 19.2±3.52 |           | p=0.021 HPR of RZ in RUL RFA group vs. sham group |
|       |         |           |           | p=0.87 HPR of RZ in RLL RFA group vs. sham group |
| **C, HPR value (%) in TZ and RZ at day 14 following RFA**     |
| Group | TZ     | RZ in RUL | RZ in RLL | P-value |
|-------|--------|-----------|-----------|---------|
| RFA   | 52.6±9.89 | 40.3±5.69 | 27.9±4.39 | p=0.009 TZ vs. RZ in RLL of RFA group |
|       |         |           |           | p=0.026 TZ vs. RZ in RUL of RFA group |
| Sham  | 29.8±4.53 | 28.5±4.74 |           | p=0.019 HPR of RZ in RUL RFA group vs. sham group |
|       |         |           |           | p=0.89 HPR of RZ in RLL RFA group vs. sham group |
| TZ, transition zone; RZ, reference zones; RFA, radiofrequency ablation; RUL, right upper lobe; RLL, right lower lobe. |
RFA induced a significant increase in the amount of tumor tissue in the TZ surrounding the ablated region as compared with the RZ in the same lobe (day 1 TZ, 32.4±5.62% vs. RZ, 19.6±3.46%, p=0.008; day 7 TZ, 39.8±7.62% vs. RZ, 25.6±4.42%, p=0.011; day 14 TZ, 52.6±8.92% vs. RZ, 40.3±5.69%, p=0.026). There was an ~2-fold increase in the TZ compared with the RZ in the RLL (day 1 TZ, 32.4±5.62% vs. RZ, 14.8±2.98%, p=0.000; day 7 TZ, 39.8±7.62% vs. RZ, 19.9±3.98%, p=0.001; day 14 TZ, 52.6±9.89% vs. RZ, 27.9±4.39%, p=0.006) (Fig. 3A-C; Table I A-C).

These results indicated that RFA treatment induced the proliferation of tumors in the ablated lobe, but did not affect the tumor on the ipsilateral side of the other lobe. In the ablated lobe, the tumor in the TZ surrounding the ablated region had a higher proliferative capacity than the tumor in the distant areas. The tumor microenvironment may have been altered by RFA treatment, which could help to account for these differences. Therefore, we explored the expression of tumor-relevant regulatory factors within the tumor microenvironment.

Accelerated tumor proliferation in the TZ and RZ is associated with HIF-1α expression. Based on the immunohistochemical results (Fig. 4A-C) and semi-quantitative analysis, the highest HIF-1α expression level occurred in the TZ at day 1 following RFA treatment (TZ, 31.4±4.43% vs. RZ in RUL, 24.5±5.79%, p=0.019; TZ, 31.4±4.43% vs. RZ in RLL, 10.9±3.21%, p=0.001) (Fig. 4D; Table IIA). At day 1, 7 and 14 following RFA treatment, HIF-1α expression in the RZ of the RUL was significantly higher in the RFA than the RZ of the RLL. Day 1, *p=0.005 RZ in RUL vs. RZ in RLL; day 7, *p=0.011 RZ in RUL vs. RZ in RLL; day 14, *p=0.021 RZ in RUL vs. RZ in RLL. (E) Treatment with YC-1 decreased the PRA value significantly: *p≤0.001, RFA group vs. RFA + YC-1 group at day 1, 7 and 14. (F and G) PRA value of RZ in RUL and RLL decreased in the RFA + YC-1 group at days 1, 7 and 14: *p<0.01, RFA group vs. RFA + YC-1 group. Meanwhile in the sham group, the PRA value also decreased after treatment with YC-1: *p<0.05 sham vs. YC-1 group.
more significantly increased HIF-1α expression in the RZ of the ablated lobe in RUL than RZ of the non-ablated lobe in RLL at day 1, 7 and 14 (RZ of RUL vs. RZ of RLL: day 1, 24.5±5.97% vs. 10.9±3.21%, p=0.005; day 7, 20.3±4.35% vs. 9.1±2.98%, p=0.011; day 14, 12.5±3.96% vs. 6.4±2.78%, p=0.021) (Fig. 4D; Table IIA-C). Following treatment with YC-1, an inhibitor of HIF-1α, the PRA value in the TZ significantly decreased at days 1, 7 and 14 following RFA (RFA group vs. RFA + YC-1 group: day 1, 32.4±5.62% vs. 10.8±2.34%, p=0.000; day 7, 39.8±7.62% vs. 16.6±3.98%, p=0.000; day 14, 52.6±9.89% vs. 23.5±4.74%, p=0.001) (Fig. 4E; Table II A-C). In addition to the TZ, tumor proliferation capacity was also inhibited by YC-1 in the RZ of the RUL and RLL, regardless of RFA treatment (Fig. 4F and G; Table IIIA and B; data not shown). These data suggest that tumor proliferation was universally induced by HIF-1α and can be suppressed by inhibiting HIF-1α. Thermal stimulus had the greatest impact on HIF-1α expression; HIF-1α reached its highest expression levels in the TZ surrounding the central necrotic zone. In addition, RFA treatment induced HIF-1α expression in the distant region (RZ) of the ablation zone.

**Table II. HIF-1α expression (%) in TZ and RZ at days 1, 7 and 14 following RFA.**

| Group | TZ       | RZ in RUL  | RZ in RLL  | P-value |
|-------|---------|------------|------------|---------|
| RFA   | 31.4±4.43 | 24.5±5.97  | 10.9±3.21  | p=0.001 RFA group: TZ vs. RZ in RLL p=0.028 RFA group: TZ vs. RZ in RUL p=0.019 RZ in RUL: RFA group vs. sham group p=0.08 RZ in RLL: RFA group vs. sham group p=0.005 RFA group: RZ in RUL vs. RZ in RLL |
| Sham  | 11.7±3.03 | 11.1±3.24  |            |         |

**Table II B. HIF-1α expression (%) in TZ and RZ at day 7 following RFA.**

| Group | TZ       | RZ in RUL  | RZ in RLL  | P-value |
|-------|---------|------------|------------|---------|
| RFA   | 25.4±5.01 | 20.3±4.35  | 9.1±2.98   | p=0.007 RFA group: TZ vs. RZ in RLL p=0.037 RFA group: TZ vs. RZ in RUL p=0.011 RZ in RUL: RFA group vs. sham group p=0.011 RZ in RLL: RFA group vs. sham group p=0.011 RFA group: RZ in RUL vs. RZ in RLL |
| Sham  | 10.3±3.32 | 9.2±2.64   |            |         |

**Table II C. HIF-1α expression (%) in TZ and RZ at day 14 following RFA.**

| Group | TZ       | RZ in RUL  | RZ in RLL  | P-value |
|-------|---------|------------|------------|---------|
| RFA   | 19.7±4.97 | 12.5±3.96  | 6.4±2.78   | p=0.000 RFA group: TZ vs. RZ in RLL p=0.014 RFA group: TZ vs. RZ in RUL p=0.017 RZ in RUL: RFA group vs. sham group p=0.011 RZ in RLL: RFA group vs. sham group p=0.021 RFA group: RZ in RUL vs. RZ in RLL |
| Sham  | 6.7±2.13  | 6.9±1.58   |            |         |

HIF-1α, hypoxia inducible factor-1α; TZ, transition zone; RZ, reference zones; RFA, radiofrequency ablation; RUL, right upper lobe; RLL, right lower lobe.

**Tissue angiogenesis potential is also regulated by HIF-1α, but has no effect on tumor proliferation in the TZ.** As demonstrated, accelerated tumor growth in the TZ or RZ of the ablated lobe following RFA was found to be associated with activation of HIF-1α. Our previous study indicated that HIF-1α can induce the expression of multiple angiogenic cytokines, while upregulating the angiogenesis potential of SCLC cells. Therefore, we set out to determine whether tissue angiogenesis acts as the driving force in RFA-stimulated micrometastasis growth. To assess the effects on the growth of micrometastases by angiogenesis, we analyzed the microvessel density (MVD) as CD34-positive stained areas to compare the angiogenesis potential of the TZ and RZ in the RUL and RLL (Fig. 5A-C). At days 1, 7 and 14 following RFA treatment, the TZ exhibited a higher angiogenesis potential in the CD34-positive area compared with the RZ in the RUL (such as: day 1 TZ, 156.7±30.99% vs. RZ, 127.8±24.34%, p=0.01) and RZ in RLL (such as: day 1, TZ, 156.7±30.99% vs. RZ, 119.8±19.90%, p=0.002) (Fig. 5D, Table IVA-C). Treatment with YC-1 reduced CD34 expression in all zones following RFA (day 1 TZ, 156.7±30.99% vs. 82.2±20.67% p=0.00; RZ...
in RUL: 127.8±24.34% vs. 43.1±8.65% p=0.00; RZ in RLL: 119.8±19.90% vs. 37.8±7.12% p=0.000) (Fig. 5D; Table IVA-C). However, treatment with the vascular specific inhibitor PTK/ZK did not alter tumor growth in the TZ (day 1 PRA of TZ: 32.4±5.62 vs. 31.6±5.37, p=0.87), which was different from the results of the RZ in the RUL and RLL (Fig. 5E; Table VA-C; data not shown). Our data indicated that HIF-1α regulates tumor growth by inducing tissue angiogenesis in the RZ of the RUL and the RLL. However, in the TZ in RFA-treated mice, tumor growth was not associated with tissue angiogenesis potential, although regulated by HIF-1α.

In conclusion, we found the following. i) Following RFA treatment, the TZ formed between the central necrotic zone and the unaffected RZ along with the micrometastasis in this zone exhibited stronger proliferative activity and higher HIF-1α expression levels than the other zones. The growth of micrometastases in the TZ was induced by HIF-1α, but was not associated with the tissue angiogenesis potential. ii) In the RZ of the ablated or unablated lobe, HIF-1α induced the growth of micrometastases by regulating tissue angiogenesis potential.

Discussion

Radiofrequency ablation (RFA) is a thermal ablative technique and a relatively new modality of treatment, which may be applicable in high-risk patients with lung cancer (18). Compared with radiotherapy and chemotherapy, RFA is focused exclusively on the tumor area and does not damage the normal surrounding tissue. Compared with surgical intervention, RFA is minimally invasive. For advanced lung cancers, including small cell lung cancer (SCLC), RFA also can enhance palliative treatment (19). In general, RFA appears to be a safe procedure with limited/minimal morbidity and mortality (20). The most common operation complication appears to be the occasional development of a pneumothorax or hemothorax. However, with the progression in hemostasis techniques and surgical repair materials, the incidence of these complications will be significantly reduced (21). Although RFA has been increasingly more widely used for the treatment of lung cancer, postoperative recurrence is still a major shortcoming of this therapy (8). Various scholars argue that recurrences may be managed or mitigated based on a careful distinction of the recurrence site. Based on this concept, when regional hilar mediastinal lymphatic metastasis or distant relapse occurs, patients should be considered as affected by systemic tumor factors; initial ablation was probably complete, but the stage was underestimated and the patients should be managed by systemic therapy. If a tumor recurrence occurs in the local area surrounding the ablation zone, patients should be considered as being affected by the local tumor microenvironmental changes, and ablation was probably incomplete (22).
associated with an increased rate of local recurrence, which emphasizes the importance of obtaining satisfactory ablative margins (23). However, even when complete tumor destruction is achieved and satisfactory ablation margins have been created, residual tumor cells could survive in the transition zone (TZ) between the necrosis induced by RFA and the normal tissue (24). Therefore, a new opinion was put forward that the biological characteristics of the microenvironment in the TZ are critically important in the timing and prognosis of tumor local recurrences (25). Stoeckelhuber et al proposed that a clear demarcation between the ablation zones and TZs should be the criterion used to judge the success of RFA treatment. Applicable parameters of RFA, such as ablation temperature, time and the depth of needle-electrode puncture were selected as sentinels according to the results of immunohistochemistry and hematoxylin and eosin (H&E) staining. The parameters of RFA that result in the maximum diameter of the ablation zone and the maximum width of the TZ were selected for treatment (26). Thermal destruction therapies will unequivocally produce a TZ, such that the growth of residual tumor cells that are located in the TZ may be accelerated and cause local recurrences (27).

Figure 5. Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed CD34-positive staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the CD34-positive stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. *P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; **P<0.05, RFA group: TZ vs. RZ in RUL; ***P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the TZ of the RUF and RLL. ※P>0.05, RFA group vs. RFA + PTK/ZK group; ▲P<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
In general, hyperthermia can directly inhibit the proliferation of tumor cells (28,29), while the tumor cells surviving in the TZ following RFA may overproliferate. There are two factors that may account for this phenomenon. First, hyperthermia treatment creates a local hypoxic microenvironment, which is often observed in the TZ surrounding the necrosis zone. Nikfarjam et al (33) found that following RFA treatment of liver metastases, a highly localized hypoxia-driven acceleration of tumor growth occurs in the TZ. However, angiogenesis is not the driving force behind RFA-stimulated tumor growth, indicating that other hypoxia-activated pathways are likely important (16). HIF-1α is a master regulator of the essential adaptive responses to hypoxia, which is highly expressed under hypoxic conditions and is maintained at a constant low concentration under normoxic condition (30).

In the present study, HIF-1α immunostaining was mainly localized immediately adjacent to the necrotic area, and strong HIF-1α staining was observed in tumor cells or the extracellular matrix of the TZ following RFA. After treatment with a specific inhibitor of HIF-1α (YC-1), HIF-1α expression in the TZ decreased, while the angiogenesis potential was also significantly reduced. Angiogenesis potential is critical to tumor proliferation (31), as indicated by the results of our previous studies in SCLC cells (14). HIF-1α promotes angiogenesis potential by upregulating VEGF-A expression. VEGF-A is one of the best-studied downstream effectors of HIF-1α, and it plays a pivotal role in the stimulation of hypoxia-driven angiogenesis (32). Several angiogenic factors, including VEGF-A, are upregulated primarily adjacent to the ablation zone (33). PTK787/ZK-222584, a specific inhibitor that reduces VEGF-A expression, has been widely used in the clinical treatment of SCLCs (34). However, in the present study, while PTK/ZK largely inhibited the angiogenic response, it had no significant effect on tumor proliferation in the TZ, in sharp contrast to YC-1, which reduced proliferation. For this reason, RFA is an important method for tumor hyperthermia and can destroy tumor cells by generating high temperatures. Heat shock proteins (HSPs), synthesized under heat stress, can facilitate recovery of tumor cells from heat damage (35).

MVD, microvessel density; TZ, transition zone; RZ, reference zones; RFA, radiofrequency ablation; RUL, right upper lobe; RLL, right lower lobe.

| Group      | TZ        | RZ in RUL | RZ in RLL | P-value                                  |
|------------|-----------|-----------|-----------|------------------------------------------|
| RFA        | 156.7±30.99 | 127.8±24.34 | 119.8±19.9 | TZ: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RUL: p=0.004 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RLL: p=0.000 RFA group vs. RFA + YC-1 group |
| RFA + YC-1 | 82.2±20.67 | 43.1±8.65 | 37.8±7.12 | p=0.047 RFA group: TZ vs. RZ in RLL |
|            |           |           |           | p=0.025 RFA group: TZ vs. RZ in RUL |

| Group      | TZ        | RZ in RUL | RZ in RLL | P-value                                  |
|------------|-----------|-----------|-----------|------------------------------------------|
| RFA        | 121.3±32.3 | 89.6±21.1 | 83.7±19.8 | TZ: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RUL: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RLL: p=0.000 RFA group vs. RFA + YC-1 group |
| RFA + YC-1 | 65.4±13.7 | 35.6±7.65 | 32.1±7.08 | p=0.017 RFA group: TZ vs. RZ in RLL |
|            |           |           |           | p=0.020 RFA group: TZ vs. RZ in RUL |

| Group      | TZ        | RZ in RUL | RZ in RLL | P-value                                  |
|------------|-----------|-----------|-----------|------------------------------------------|
| RFA        | 94.1±22.3 | 76.5±21.5 | 74.3±19.8 | TZ: p=0.008 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RUL: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RLL: p=0.001 RFA group vs. RFA + YC-1 group |
| RFA + YC-1 | 43.1±12.14 | 21.6±8.32 | 24.7±7.63 | p=0.044 RFA group: TZ vs. RZ in RLL |
|            |           |           |           | p=0.049 RFA group: TZ vs. RZ in RUL |

### Table IV. MVD (mm²) in TZ and RZ at days 1, 7 and 14 following RFA.

#### A, MVD (mm²) in TZ and RZ at day 1 following RFA

| Group      | TZ        | RZ in RUL | RZ in RLL | P-value                                  |
|------------|-----------|-----------|-----------|------------------------------------------|
| RFA        | 156.7±30.99 | 127.8±24.34 | 119.8±19.9 | TZ: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RUL: p=0.004 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RLL: p=0.000 RFA group vs. RFA + YC-1 group |
| RFA + YC-1 | 82.2±20.67 | 43.1±8.65 | 37.8±7.12 | p=0.047 RFA group: TZ vs. RZ in RLL |
|            |           |           |           | p=0.025 RFA group: TZ vs. RZ in RUL |

#### B, MVD (mm²) in TZ and RZ at day 7 following RFA

| Group      | TZ        | RZ in RUL | RZ in RLL | P-value                                  |
|------------|-----------|-----------|-----------|------------------------------------------|
| RFA        | 121.3±32.3 | 89.6±21.1 | 83.7±19.8 | TZ: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RUL: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RLL: p=0.000 RFA group vs. RFA + YC-1 group |
| RFA + YC-1 | 65.4±13.7 | 35.6±7.65 | 32.1±7.08 | p=0.017 RFA group: TZ vs. RZ in RLL |
|            |           |           |           | p=0.020 RFA group: TZ vs. RZ in RUL |

#### C, MVD (mm²) in TZ and RZ at day 14 following RFA

| Group      | TZ        | RZ in RUL | RZ in RLL | P-value                                  |
|------------|-----------|-----------|-----------|------------------------------------------|
| RFA        | 94.1±22.3 | 76.5±21.5 | 74.3±19.8 | TZ: p=0.008 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RUL: p=0.000 RFA group vs. RFA + YC-1 group |
|            |           |           |           | RZ in RLL: p=0.001 RFA group vs. RFA + YC-1 group |
| RFA + YC-1 | 43.1±12.14 | 21.6±8.32 | 24.7±7.63 | p=0.044 RFA group: TZ vs. RZ in RLL |
|            |           |           |           | p=0.049 RFA group: TZ vs. RZ in RUL |
survival, including HIF-1α (36). HSP70 plays an important role in protecting cell death from a variety of stresses and the upregulation of inducible HSP70 expression can stabilize HIF-1α expression through p85α mediation (37). Thus, it is speculated that upregulation of expression of HIF-1α in TZ and RZ of RUL may be induced by HSPs (HSP90 or HSP70) following RFA treatment. VEGF is one of the best studied downstream effectors of HIF and plays a pivotal role in the stimulation of hypoxia-driven angiogenesis (14). Meanwhile, HSP70-HSP90 heat shock protein can also stimulate degradation of endothelial VEGFR and inhibit the angiogenesis of tumors (38). Therefore, we believe that the angiogenesis in TZ is regulated to a great extent by HSP and cannot independently affect the growth of tumors in the TZ. Thus, inhibition of angiogenesis in the TZ following RFA treatment had no significant effect on the overproliferation of residual SCLC cells. Hence, HSPs/HIF-1α may play a vital role in regulating the proliferation rate of residual SCLC cells in TZ and the underlying specific molecular mechanism involved in the regulation of HIF-1α expression by HSPs will be investigated in our future study.

RFA has been proposed as an acceptable alternative for the treatment of SCLCs. Although this technique and the conditions of ablation have been improved by applying multipolar ablation or widening the ablation margin, local recurrence is still common. Multidisciplinary synthetic therapy, which is RFA combined with another treatment has subsequently gained appeal. Recently, adjuvant treatments used in combination with thermal destruction therapies such as RFA have mainly involved the addition of cytotoxic agents (39). In preclinical tests, the combination of RFA with doxorubicin-based chemotherapy created an increase in coagulation size and reduced the risk of recurrence (40). As accelerated overproliferation (elicited by RFA) was associated with hypoxia in our study, hypoxia-activated prodrugs may be efficacious in the adjuvant treatment of SCLCs following RFA. Molecular-targeted therapy against HIF-1α may also prove to be a suitable adjuvant treatment for RFA. In addition, hyperthermia may elicit an antitumor T cell response by presenting tumor antigens to the immune system, ultimately resulting in the inhibition of tumor proliferation (41). Our future study will focus on developing methods to induce an antitumor immune response. Our study provides a theoretical basis for the development of new multidisciplinary synthetic therapies for SCLCs typically treated with RFA alone.

Acknowledgements

The present study was funded by the National Nature Science Foundation of China (no. 81302028). The authors would like to thank the Duoease Scientific Service Center for excellent language editing service and suggestions for Figure revision.

Table V. PRA value (%) in TZ, in RZ of RUL and in RZ of RLL at days 1, 7 and 14.

A, PRA value (%) in TZ

| Group          | Day 1   | Day 7   | Day 14  | P-value                      |
|----------------|---------|---------|---------|------------------------------|
| RFA            | 32.4±5.62 | 39.8±7.62 | 52.6±9.89 | Day 1: p=0.079 RFA group vs. RFA + YC-1 group  |
|                |         |         |         | Day 7: p=0.088 RFA group vs. RFA + YC-1 group |
| RFA + PTK/ZK   | 31.6±5.37 | 37.9±7.64 | 54.5±10.1  | Day 14: p=0.091 RFA group vs. RFA + YC-1 group |

B, PRA value (%) in RZ of RUL

| Group          | Day 1   | Day 7   | Day 14  | P-value                      |
|----------------|---------|---------|---------|------------------------------|
| RFA            | 19.6±3.46 | 25.6±4.42 | 40.3±5.69 | Compared with RFA group and RFA + PTK/ZK group; |
| RFA + PTK/ZK   | 11.1±2.79 | 14.6±2.98 | 20.7±3.01 | Day 1: p=0.028, day 7: p=0.021, day 14: p=0.014 |
| Sham           | 15.9±3.43 | 18.9±3.99 | 29.8±4.53 | Compared with sham group and PTK/ZK group; |
| PTK/ZK         | 7.2±1.96  | 8.6±1.37  | 13.4±2.64  | Day 1: p=0.037, day 7: p=0.025, day 14: p=0.017 |

C, PRA value (%) in RZ of RLL

| Group          | Day 1   | Day 7   | Day 14  | P-value                      |
|----------------|---------|---------|---------|------------------------------|
| RFA            | 14.8±2.98 | 19.9±3.98 | 27.9±4.39 | Compared with RFA group and RFA + PTK/ZK group; |
| RFA + PTK/ZK   | 9.6±3.01  | 9.8±2.65  | 12.1±3.12 | Day 1: p=0.038, day 7: p=0.017, day 14: p=0.009 |
| Sham           | 14.5±2.62 | 19.2±3.52 | 28.5±4.74 | Compared with sham group and PTK/ZK group; |
| PTK/ZK         | 10.1±2.89 | 10.6±2.95 | 14.2±3.67  | Day 1: p=0.047, day 7: p=0.015, day 14: p=0.007 |

TZ, transition zone; RZ, reference zones; RFA, radiofrequency ablation; RUL, right upper lobe; RLL, right lower lobe.
References

1. Varela G and Thomas PA: Surgical management of advanced non-small cell lung cancer. J Thorac Dis 6 (Suppl 2): S217-S223, 2014.

2. Schreiner W, Sermrau S, Fietkau R and Sirbu H: Oligometastatic non-small cell lung cancer - surgical options and therapy strategies. Zentralbl Chir 139: 335-341, 2014 (In German).

3. Bolca C, Dănilă O, Paleru C and Cordoș I: Role of surgery in small cell lung cancer. Pneumologia 62: 236-238, 2011 (In Romanian).

4. Hosono MN, Hosono M, Endo K, Ueda R and Oonaga Y: Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J Nucl Med 35: 504-509, 1994.

5. Kawahara T, Ito H, Terao H, Kato Y, Uemura H, Kubota Y and Matsuaki J: Effectiveness of ureteroscopy-assisted retrograde nephroscopy (UARN) for percutaneous nephrolithotomy (PCNL). PLOS One 7: e52149, 2012.

6. Alexander ES and Dupuy DE: Lung cancer ablation: Technologies and techniques. Semin Intervent Radiol 30: 141-150, 2013.

7. Roberton BJ, Liu D, Power M, Wan JM, Stuart S, Klass D and Yee J: Pulmonary ablation: A primer. Can Assoc Radiol J 65: 177-185, 2014.

8. Lanuti M, Sharma A, Willers H, Digumarthy SR, Mathisen DJ and Shepard JA: Radiofrequency ablation for stage I non-small cell lung cancer: Management of locoregional recurrence. Ann Thorac Surg 93: 921-927, discussion 927-988, 2012.

9. Tang Y, Fozzato A, Geselle GS, Compton CC, Gazelle GS, Mueller PR and Tanabe KK: Treatment of intrahepatic malignancy with radiofrequency ablation: Radiologic-pathologic correlation. Cancer 88: 2452-2463, 2000.

10. Yamada S, Utsunomiya T, Morine Y, Irimura S, Ikemoto M, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, and Shepard JA: Expression of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol 21 (Suppl 3): S436-S442, 2014.

11. Beland MD, Wasser EJ, Mayer-Smith WW and Dupuy DE: Primary non-small-cell lung cancer: Review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 254: 301-307, 2010.

12. Fraga A, Ribeiro R and Medeiros R: Tumor hypoxia: The role of HIF. Actas Urol Esp 33: 941-951, 2009 (In Spanish).

13. Wan J, Ma J, Mei J and Shan G: The effects of HIF-1alpha on angiogenic potential in human small cell lung cancer cells. J Exp Clin Cancer Res 28: 150, 2009.

14. Wan J, Chai H, Yu Z, Ge W, Kang N, Xia W and Che Y: HIF-1α effects on angiogenic potential in human small cell lung carcinoma. J Exp Clin Cancer Res 30: 77, 2011.

15. Tsui L, Fong TH and Wang SS: Targeting of hypoxia-inducible factor-1 reduces RGC-5 cell viability and inhibits cell proliferation. Mol Vis 18: 1594-1603, 2012.

16. Nijkamp MW, Borren A, Govaert KM, Hoogwater FJ, Stoeckelhuber BM, Noack F, Kapsimalakou S, Rudolf I, Bergmann-Koester CU, Helmberger T and Stoeckelhuber M: Radiofrequency ablation in breast tissue: Experimental study for evaluation of radiofrequency effects in the bovine udder and review of the literature. J Vase Interv Radiol 20: 1477-1482, 2009.

17. Bai A, Ravegvia F, De Simone M and Cioffi U: Palliative role of radiofrequency ablation in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 94: 1788-1789, 2012.

18. Bott MJ and Crabtree T: Treatment of stage I lung cancer in high-risk and inoperable patients: SBRT vs. RFA vs. sublobar resection. Ann Cardiothorac Surg 3: 167-169, 2014.

19. Baisi A, Raveglia F, De Simone M and Cioffi U: Recurrence after radiofrequency ablation for stage I non-small cell lung cancer. Ann Thorac Surg 94: 158-167, 2012.

20. Kelekis AD, Thanos L, Mylona S, Arsenis S and Ptohis N: Palliative role of radiofrequency ablation for severe hemoptysis in an elderly patient with inoperable lung cancer. J Thorac Cardiovasc Surg 140: 1196-1197, 2010.

21. Schreiner W, Sermrau S, Fietkau R and Sirbu H: Oligometastatic non-small cell lung cancer - surgical options and therapy strategies. Zentralbl Chir 139: 335-341, 2014 (In German).

22. Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J and Nakatsuka A: Complications after 1000 lung radiofrequency ablation for stage I non-small cell lung cancer. AJR Am J Roentgenol 197: W576-W580, 2011.

23. Bruns AF, Yuldasheva N, Latham AM, Bao L, Pellet-Many C, Strawbridge R, Hoopes PJ and Khan N: Heat shock protein expression analysis in canine osteosarcoma reveals HSPI0 as a potentially relevant therapeutic target. Cell Stress Chaperones 18: 607-622, 2013.

24. Nijkamp MW, Borren A, Govaert KM, Hoogwater FJ, Stoeckelhuber BM, Noack F, Kapsimalakou S, Rudolf I, Bergmann-Koester CU, Helmberger T and Stoeckelhuber M: Radiofrequency ablation of colorectal liver metastases induces an inflammatory response in distant hepatic metastases but not in local accelerated outgrowth. J Surg Oncol 101: 551-556, 2010.

25. Stoeckelhuber BM, Noack F, Kapsimalakou S, Rudolf I, Bergmann-Koester CU, Helmberger T and Stoeckelhuber M: Radiofrequency ablation in breast tissue: Experimental study for evaluation of radiofrequency effects in the bovine udder and review of the literature. J Vase Interv Radiol 20: 1477-1482, 2009.

26. Bott MJ and Crabtree T: Treatment of stage I lung cancer in high-risk and inoperable patients: SBRT vs. RFA vs. sublobar resection. Ann Cardiothorac Surg 3: 167-169, 2014.

27. Frich L, Bjørnland K, Pettersen S, Clausen S, Olsen P, Rehnström P, Jansen S, Hansen M, Sørensen E and Mork R: Palliative role of radiofrequency ablation for severe hemoptysis in an elderly patient with inoperable lung cancer. J Thorac Cardiovasc Surg 94: 1788-1789, 2012.

28. Takagi H, Azuma K, Tsuka T, Imagawa T, Osaki T and Okamoto Y: Antitumor effects of high-temperature hyperthermia on a glioma rat model. Oncol Lett 7: 1007-1010, 2014.

29. Chen EY, Samkoe KS, Hodge S, Tai K, Hou H, Petrisky AA, Strawbridge R and Khan N: Heat induction of the unphosphorylated form of hypoxia-inducible factor α by magnetic nanoparticle hyperthermia to augment therapeutic index. Adv Exp Med Biol 812: 87-95, 2014.

30. Brocot A, Schindler G and Hooper RH: Heat shock protein expression in canine osteosarcoma reveals HSPI0 as a potentially relevant therapeutic target. Cell Stress Chaperones 18: 607-622, 2013.

31. Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, Bergmann-Koester CU, Helmberger T and Stoeckelhuber M: Radiofrequency ablation of colorectal liver metastases induces an inflammatory response in distant hepatic metastases but not in local accelerated outgrowth. J Surg Oncol 101: 551-556, 2010.

32. Shahneh FZ, Baradan B, Zamani F and Aghebati-Maleki L: Tumor angiogenesis and anti-angiogenic therapies. Hum Antibodies 22: 15-19, 2013.

33. Nijkamp MW, Baisi A, Raveglia F, De Simone M and Cioffi U: Recurrence after radiofrequency ablation for stage I non-small cell lung cancer. Ann Thorac Surg 94: 1788-1789, 2012.